FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Библиотека пептидов

Mazdutide

LY3305677 / IBI362

Weight Loss & Metabolic

Mazdutide (LY3305677/IBI362) is a GLP-1/glucagon receptor dual agonist co-developed by Innovent Biologics and Eli Lilly, primarily advancing through clinical development in China. It activates both GLP-1 receptors for appetite suppression and glucagon receptors for enhanced energy expenditure and hepatic fat reduction. The compound is in Phase 3 clinical trials for obesity and type 2 diabetes in the Chinese market.

Механизм действия

Dual GLP-1/glucagon receptor agonist. Promotes direct hepatic fat oxidation and thermogenesis alongside appetite suppression.

Протоколы исследований

Только для исследовательских целей. Не медицинская консультация.

Phase 3 research protocols use 4mg to 9mg biweekly subcutaneous injection.

Примечания к исследованиям

Clinical Research Status

Mazdutide has completed multiple Phase 3 trials in China, with regulatory submission to China's NMPA anticipated or underway. The GLORY Phase 3 program demonstrated up to 14.4% body weight loss at 48 weeks in Chinese patients with obesity. Innovent holds rights for the Chinese market while Eli Lilly retains rights for other territories, though global development timelines remain less defined.

Key Published Findings

Phase 2/3 data showed dose-dependent weight loss with the 6mg and 9mg doses demonstrating the strongest efficacy. The glucagon receptor component is hypothesized to increase energy expenditure and promote hepatic lipid oxidation beyond what GLP-1 agonism alone achieves. HbA1c reductions of 1.5-2.0% have been observed in diabetic populations, suggesting robust dual metabolic benefit.

Safety Profile

Gastrointestinal adverse events remain the most common class effect, with nausea and diarrhea reported in 20-40% of patients during titration. The glucagon component raises theoretical concerns about hepatic glucose output, though hyperglycemia has not emerged as a significant finding in clinical data. Heart rate increases have been observed, consistent with GLP-1 agonist class effects, and long-term cardiovascular outcome data is not yet available.

Comparison to Related Compounds

Mazdutide shares the dual GLP-1/glucagon mechanism with survodutide (Boehringer Ingelheim) but has advanced further in regulatory timelines within China. Unlike tirzepatide which targets GIP/GLP-1, mazdutide's glucagon component is designed to boost energy expenditure rather than enhance incretin signaling. The weight loss magnitude appears intermediate between semaglutide monotherapy and the highest tirzepatide doses.

Community Observations

Mazdutide represents one of the most advanced obesity therapeutics developed primarily for the Asian market, where metabolic disease prevalence is rising rapidly. Researchers note the glucagon component may offer particular benefit for NAFLD/MASH given glucagon's role in hepatic fat metabolism. The compound's development trajectory illustrates the growing importance of the Chinese pharmaceutical market for peptide therapeutics.

Половая жизнь

~5-6 days

Реконституция

Bacteriostatic water (BAC)

Хранение

Лиофилизированный

Refrigerate 2-8C. Protect from light.

Реконститутированный

Refrigerate 2-8C. Use within 21 days.

Юридический статус США

Research chemical (not FDA-approved)

Также известен как

LY3305677IBI362

Часто задаваемые вопросы

Что такое Mazdutide?

Mazdutide (LY3305677/IBI362) is a GLP-1/glucagon receptor dual agonist co-developed by Innovent Biologics and Eli Lilly, primarily advancing through clinical development in China. It activates both GLP-1 receptors for appetite suppression and glucagon receptors for enhanced energy expenditure and hepatic fat reduction. The compound is in Phase 3 clinical trials for obesity and type 2 diabetes in the Chinese market.

Как действует Mazdutide?

Dual GLP-1/glucagon receptor agonist. Promotes direct hepatic fat oxidation and thermogenesis alongside appetite suppression.

Каков регуляторный статус Mazdutide в США?

Research chemical (not FDA-approved)

Каков период полувыведения Mazdutide?

~5-6 days

Как ещё называют Mazdutide?

LY3305677, IBI362

Peptide Contacts предоставляет исследовательские сводки только для информационных целей. Мы не хостим, распространяем или одобряем документацию поставщиков. Все сертификаты анализа, GMP-сертификаты и коммуникации с поставщиками должны быть запрослены и проверены непосредственно покупателем. Ничто на этом платформе не является юридическим, медицинским или профессиональным советом. Пользователи самостоятельно отвечают за проверку квалификаций поставщиков и обеспечение соответствия всем применимым местным, штатным и федеральным законам перед покупкой любых исследовательских химикатов. Использование этой платформы означает принятие полной личной ответственности.

Прочитать полное заявление о неприкосновенности